DWA
OPNT

Dorsey Wright & Associates’s Opiant Pharmaceuticals, Inc. Common Stock OPNT Stock Holding History

Dorsey Wright & Associates’s Portfolio OPNT Stock Details OPNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,138
Closed -$72K – 359
2021
Q4 		$72K Buy
+2,138
New +$59.6K 0.01% 172

Other funds holding OPNT

Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
OCM
Ovata Capital Management Hong Kong $1.33B AUM 5.69% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
ACA
Apis Capital Advisors New York $648M AUM 302.67% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Dorsey Wright & Associates's OPNT Position: Q1 2022 in Review

Dorsey Wright & Associates sold out of Opiant Pharmaceuticals, Inc. Common Stock (OPNT) in Q1 2022, closing a stake of 2,138 shares — an estimated $72K sold.

Dorsey Wright & Associates first reported a position in OPNT in Q4 2021 and held it in 1 quarter. The position peaked at $72K in Q4 2021. 41 funds tracked by Wall St. Rank hold OPNT as of Q1 2022.

  • Dorsey Wright & Associates reported no remaining Opiant Pharmaceuticals, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Dorsey Wright & Associates sold 2,138 Opiant Pharmaceuticals, Inc. Common Stock shares in Q1 2022, an estimated $72K.
  • Dorsey Wright & Associates first reported a position in Opiant Pharmaceuticals, Inc. Common Stock in Q4 2021 and held it in 1 quarter.
  • Dorsey Wright & Associates's Opiant Pharmaceuticals, Inc. Common Stock position peaked at $72K in Q4 2021.
  • 41 funds tracked by Wall St. Rank held Opiant Pharmaceuticals, Inc. Common Stock as of Q1 2022.

Based on Dorsey Wright & Associates's 13F filing for Q1 2022, filed 27 Apr 2022.